RxDoctor Payments Data

Stephen Skiano, PA

Physician Assistant · Tucson, AZNPI 1750864310

Payments from drug & device makers

$7,115in general payments, 2019–2025

Across 351 payments — averaging $20.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Alkermes, Inc.$818
  • Johnson & Johnson$803
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$644
  • USWM, LLC$588
  • Otsuka America Pharmaceutical, Inc.$481
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$6,54992%
  • Education$591%
  • Gifts$5067%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,115 in reported general payments places this provider in the 95th percentile of 2,888 physician assistant providers in Arizona.

See all physician assistant providers in Arizona

Medicare billing

Part B allowed, 2024
$17,311
Medicare patients
18
Services billed
275

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl39$52,679
VyvanseLisdexamfetamine Dimesylate30$12,186
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl53$7,192
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine46$2,010
Quetiapine Fumarate57$1,494
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine26$1,465
Duloxetine Hcl31$1,177
Buspirone Hcl40$1,115
Clonazepam53$1,087
Ondansetron OdtOndansetron29$971
Propranolol Hcl46$887
Trazodone Hcl47$631
Quetiapine Fumarate ErQuetiapine Fumarate13$582
Lamotrigine33$536
Bupropion XlBupropion Hcl22$445

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$803$52,67939 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$99$12,18630 claims
Almatica Pharma LLCSertraline Hcl$80$23717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,888 physician assistant providers in Arizona.

Other physician assistant in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →